Diet and food supplements are of increasing interest in view of their potential in obesity management. Xanthohumol (XN) is a prenylated flavonoid found in hops, which have been used since ancient times as a medicinal plant. Traditional medicinal indications included the treatment of anxiety and insomnia, mild pain reduction or combating dyspepsia. Today, hops are used in the manufacturing of beer and female infertile plants, e.g. Humulus lupulus L, are cultivated especially for brewing. Biologically active substances, which are important for brewing, are concentrated inside hop cones in lupulin glands which contain hop resins, bitter acids, essential oils and prenylated flavonoids. For humans, beer is the major dietary source of XN. The beer content of XN varies significantly depending on the type of beer (in the range of 0.052–0.628 mg/l).
XN has also been proven to exert antioxidative, chemopreventive, and anti-inflammatory effects. It inhibits metabolic activation of food-borne carcinogens, induces phase 2 enzymes related to detoxification of xenobiotics, inhibits the PGE2 or NO production (linked to prevention of carcinogenesis),[6-8] exerts anti-tumour activity in hypoxic tumour cells. Recent studies investigating XN have also focused on the prevention and treatment of cancer.[10,11] XN has been shown to block T-cell lymphoblastic lymphomagenesis through reduction of STAT5 phosphorylation and gene up-regulated in the non-obese-diabetic STAT5bTg mice. Xanthohumol also inhibits the proliferation of lymphoma cells and IL-2 induced proliferation and cell cycle progression in mouse splenic T cells. XN exhibits anti-proliferative activity against breast, colon and ovarian cancer cell lines and is a potent inducer of chemoprevention enzymes regulated by the antioxidant response element.[14,15] So called ‘carcinoid’ cancer cell lines have also been treated with XN and this showed antiproliferative effects.
Furthermore, the female benefits of hop extracts are under investigation for their oestrogenic and are being used by women as dietary supplements and alternatives to conventional hormone replacement therapy for the management of menopausal hot flushes. One group investigated the pharmacokinetics of XN together with other three prenylated phenols following oral administration to menopausal women and reported that short-term consumption of a chemically and biologically standardized preparation of spent hops is safe for women and that once daily dosing might be appropriate. Xanthohumol and the other prenylated phenols showed long half-lives but no acute toxicity.
There is some evidence, including in vitro and animal studies that XN might exert beneficial effect in hyperlipidaemia. XN inhibits diacylglycerol acyltransferase (DGAT) and the expression of DGAT or microsomal triglyceride transfer protein (MTP) related to the lowering effects of triglyceride and apolipoprotein B.[19, 20]
XN has been suggested to have anti-atherogenic bioactivity as it is reported to decrease apolipoprotein B (apoB) secretion, inhibit triglyceride (TG) synthesis and prevent LDL oxidation in vitro. Furthermore, previous studies showed that XN reduced plaque formation in aortic lesions via reduced lipogenesis and increased faecal cholesterol excretion in apolipoprotein (apoE)-deficient mice. Moroever, XN has been reported to increase HDL cholesterol via cholesteryl ester transfer protein (CETP) inhibition in a CETP-transgenic mouse model.
Previous studies [20, 24] have shown that XN inhibits diacylglycerol acyltransferase (DGAT) activity or the expression of DGAT or microsomal triglyceride transfer protein in HepG2 cells. Those activities suggest that XN exerts TG lowering effect and amelioration of metabolic disorders in viscera. In 3T3-L1 adipocytes, Yang et al. reported reduced lipid content and decreased adipocyte marker proteins after incubation with XN. However, there have not been sufficient experiments to allow us to ascertain the molecular mechanism through which XN ameliorates metabolic disorders in vivo. Nozawa,  found that XN activated farnesoid X receptor (FXR) in vitro and modulated genes involved in lipid or glucose metabolism in mice.
Hirata et al recently investigated the effects of XN on reverse cholesterol transport in vivo and HDL cholesterol levels using a hamster model. They showed that XN improves the cholesterol efflux capacity of HDL and further enhanced in vivo reverse cholesterol transport from macrophages to faeces in hamsters. They also suggested that it may be possible to extend these findings to humans, since hamsters, like humans, express CETP, suggesting that they have a similar RCT system to humans.
Another group demonstrated that addition of XN to western-type diet ameliorates atherosclerotic plaque formation in ApoE−/− mice by positively affecting plasma cholesterol and MCP-1 concentrations and hepatic lipid metabolism via activation of AMP-activated protein kinase (AMPK). Therefore, the atheroprotective effects of XN might be attributed to combined beneficial effects on plasma cholesterol and monocyte chemoattractant protein 1 concentrations and hepatic lipid metabolism via activation of AMP-activated protein kinase.
Increasing cases of obesity has become a serious social problem in developed countries especially as obesity is closely related to the development of various lifestyle diseases.[28,29] Obesity develops when energy intake, in the form of food, exceeds energy expenditure  and is primarily characterized by excessive adiposity. There are two functionally and morphologically distinct types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT), both of which are mediators of energy homeostasis. In response to specific stimuli, WAT can acquire brown-like characteristics, which is called “beiging” and has been demonstrated in vivo  and in vitro  to improve the metabolic profile and increase thermogenesis.
There is some evidence derived from in vitro and animal studies that XN exerts anti-obesity effects, even if some controversy still exits.
Xanthohumol (XN) has been reported to exert anti-obesity effects in Zucker rats [34,35] and in various mouse strains.[3,36,37] Miranda et al. demonstrated that XN has bioactivities potentially useful for countering the metabolic aberrations of Metformin. In details, they showed that treating high fat diet (HFD)-fed C57BL/6 J mice orally with XN (60 mg/kg/day) reduced their plasma low-density lipoprotein-cholesterol (LDL-c, −80%), interleukin-6 (IL-6, −78%), HOMA-IR (−52%), leptin (−41%), and plasma levels of the LDL receptor-degrading enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9) (−44%) levels compared to those of vehicle/HFD control. The same group found that XN and its hydrogenated derivatives, α,β-dihydro-XN (DXN) and tetrahydro-XN (TXN) improve glucose tolerance and cognitive function in HFD-fed mice. Unlike XN, DXN and TXN are unable to form the estrogenic metabolite, 8-PN, and they themselves have negligible affinity for estrogen receptors. Therefore, the XN derivatives DXN and TXN have potential to prevent or treat the neuro-metabolic impairments associated with HFD-induced obesity and metformin without risk of liver injury and adverse oestrogenic effects.
Takahashi and collegues, in their recent study in animals, observed that dietary purified XN exerted anti-obesity effects by regulating lipid metabolism and inhibiting intestinal fat absorption in KK-Ay mice, thus, they suggested that XN may exert anti-obesity effects. Another team showed that XN suppressed the increase in body weight, mesenteric WAT, liver weight, and triacylglycerol levels in the plasma and liver through regulation of hepatic fatty acid metabolism and inhibition of intestinal fat absorption in Wistar rats fed a high-fat diet. The anti-obesity effects of XN are partly mediated by AMPK signalling pathway suggesting that XN may have potential therapeutic implications for obesity. Yang and collegues confirmed the anti-adipogenic effects of XN under in vitro conditions. Conversely, Mendes and colleagues claimed that XN does not improve the metabolic profile linked to obesity as XN may reduce adipocyte number, contributing to adipocyte hypertrophy.
The prevalence of T2DM, which is often associated to obesity, has increased dramatically in the last decades. T2DM is a chronic, multifactorial and progressive disease, which affects more than 300 million people worldwide. Diabetes is characterized by hyperglycemia due to a deficiency in insulin production and/or its resistance, which contributes to endothelial dysfunction, resulting in macro and microvascular complications.[42,43] Imbalance in kidney and heart neovascularization is seen in T2DM patients. Costa and colleagues reported that XN consumption reduced angiogenesis, vascular endothelial growth-factor receptor (VEGFR)-2 expression/activity, levels of VEGF-B and its receptors (i.e. VEGFR1 and neuropilin-1), VEGF-A and phosphofructokinase-2/fructose-2,6-bisphosphatase-3 enzyme expression, a metabolic marker present in endothelial tip cells in T2DM mice kidney. Altogether, these findings suggest that XN prevent angiogenic impairment and metabolic pathways that are implicated in the pathogenesis of T2DM, being promising compounds to mitigate the increasing number of diabetic patients and inherent health care costs. Another study by Costa and colleagues in the same year found that XN protects mice against the development of T2DM metabolic-related complications. XN was reported to reduce body weight gain, prevent insulin resistance and modulate lipid and glucose metabolic pathways, being these effected mediated by a metabolic switch from fatty acid synthesis to oxidation and by promoting muscle glucose uptake. Furthermore, Nozawa, in their in vitro and in vivo study, reported potential beneficial effects of XN on amelioration of metabolic disorders via farnesoid X receptor (FXR) action and showed the possibility for developing such FXR modulators as functional nutrients in the therapy or prevention of metabolic syndromes.
Legette et al. recently conducted a study in healthy men and women to determine basic pharmacokinetics (PK) parameters for XN with the aim to establish dose-concentration relationships and to predict dose-effect relationships in humans diagnosed with metabolic syndrome. To our knowledge, this is the first study that reports human PK parameters for XN. Xanthohumol PK shows a distinct biphasic absorption pattern with XN and isoxanthohumol (IX) conjugates being the major circulating metabolites following oral consumption of XN in humans. XN metabolism appears to be similar between animals and humans, thus allowing for translation of animal study findings to future clinical work. Based on these and previous findings [34,46] the selection of effective doses to be utilized in future clinical studies aimed at improving lipid and glucose metabolism in humans diagnosed with metabolic syndrome should be possible.
- Zanoli P, Zavatti, M. 2008. Pharmacognostic and pharmacological profile of Humulus lupulus L. J. Ethnopharmacol 116: 383–396.
- Chen L, Zhao Q, Jin H, Zhang X, Xu Y et al. 2010. Determination of xanthohumol in beer based on cloud point extraction coupled with high performance liquid chromatography. Talanta 81: 692–697.
- Nozawa H. 2005. Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-A(y) mice. Biochem Biophys Res Commun 336(3): 754-61.
- Miranda CL, Yang YH, Henderson MC, Stevens JF, Santana-Rios G, et al. 2000. Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline, mediated by cDNAexpressed human CYP1A2, Drug Metab. Dispos. 28: 1297–1302.
- Miranda CL, Aponso GL, Stevens JF, Deinzer ML, Buhler DR. 2000. Prenylated chalcones and flavanones as inducers of quinine reductase in mouse Hepa 1c1c7 cells. Cancer Lett 149: 21–29
- Zhao F, Nozawa H, Daikonnya A, Kondo K, Kitanaka S. 2003. Inhibitors of nitric oxide production from hops (Humulus lupulus L.). Biol Pharm Bull 26: 61–65.
- Zhao F, Watanabe Y, Nozawa H, Daikonnya A, Kondo K, et al. 2005. Prenylflavonoids and phloroglucinol derivatives from hops (Humulus lupulus). J Nat Prod 68: 43–49.
- Gerhauser C, Alt A, Heiss E, Gamal-Eldeen A, Klimo K, et al. 2002. Cancer chemopreventive activity of xanthohumol, a natural product derived from hop. Mol Cancer Ther 1: 959–969.
- Goto K, Asai T, Hara S, Namatame I, Tomoda H, et al. 2005. Enhanced antitumor activity of xanthohumol, a diacylglycerol acyltransferase inhibitor, under hypoxia. Cancer Lett 219: 215–22210.
- Chen PH, Chang CK, Shih CM, Cheng CH, Lin CW, et al.: The miR-204-3p-targeted IGFBP2 pathway is involved in xanthohumol-induced glioma cell apoptotic death. Neuropharmacology 110, 362–375, 2016. doi: 10.1016/j.neuropharm.2016.07.038. [PUBMED]
- Dokduang H, Yongvanit P, Namwat N, Pairojkul C, Sangkhamanon S, et al.: Xanthohumol inhibits STAT3 activation pathway leading to growth suppression and apoptosis induction in human cholangiocarcinoma cells. Oncol Rep 35, 2065–2072, 2016. doi: 10.3892/or.2016.4584. [PUBMED]
- Chen B, Yi B, Mao R, Liu H, Wang J et al.: Enhanced T Cell Lymphoma in NOD.Stat5b Transgenic Mice Is Caused by Hyperactivation of Stat5b in CD8+ Thymocytes. PLoS ONE 8, e56600, 2013. doi: 10.1371/journal.pone.0056600. [PUBMED]
- Lust S, Vanhoecke B, Janssens A, Philippe J, Bracke M, et al.: Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res 49, 844-50, 2005. doi: 10.1002/mnfr.200500045 [PUBMED].
- Miranda CL, Stevens JF, Helmrich A, Henderson MC, Rodriguez RJ, et al. 1999. Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Food Chem Toxicol 37: 271–285.
- Dietz BM, Kang YH, Liu G, Eggler AL, Yao P, et al. 2005. Xanthohumol isolated from Humulus lupulus Inhibits menadione-induced DNA damage through induction of quinone reductase. Chem Res Toxicol 18: 1296–1305.
- McManus C M, Seiler BA, Rose SL, Chen H, Kunnimaliyaan M. 2010. Xanthohumol, a novel plant extract, alters neuroendocrine phenotype and inhibits growth of carcinoid cell lines. Poster abstract, NANETS.
- Chadwick LR, Pauli GF, Farnsworth NR. 2006. The pharmacognosy of Humulus lupulus L. (hops) with an emphasis on estrogenic properties. Phytomedicine 13: 119131.
- van Breemen RB, Yuan Y, Banuvar S, Shulman LP, Qiu X, et al. 2014. Pharmacokinetics of prenylated hop phenols in women following oral administration of a standardized extract of hops. Mol Nutr Food Res 58(10): 1962-9.
- Tabata N, Ito M, Tomoda H, Omura S. 1997. Xanthohumols, diacylglycerol acyltransferase inhibitors, from Humulus lupulus. Phytochemistry 46: 683–687.
- Casaschi A, Maiyoh GK, Rubio BK, Li RW, Adeli K, et al. 2004. The chalcone xanthohumol inhibits triglyceride and apolipoprotein B secretion in HepG2 cells. J Nutr 134: 1340–1346.
- Liu M, Hansen PE, Wang G, Qiu L, Dong J, et al. 2015. Pharmacological profile of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus). Molecules. 20: 754-79.
- Doddapattar P, Radović B, Patankar JV, Obrowsky S, Jandl K, et al. 2013. Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice. Mol Nutr Food Res 57: 1718-28.
- Hirata H, Yimin, Segawa S, Ozaki M, Kobayashi N, et al. 2012. Xanthohumol prevents atherosclerosis by reducing arterial cholesterol content via CETP and apolipoprotein E in CETP-transgenic mice. PLoS One 7: e49415.
- Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497–509.
- Yang JY, Della-Fera MA, Rayalam S, Baile CA. 2007. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis 12: 1953–1963.
- Hirata H, Uto-Kondo H, Ogura M, Ayaori M, Shiotani K, et al. 2017. Xanthohumol, a hop-derived prenylated flavonoid, promotes macrophage reverse cholesterol transport. J Nutr Biochem 47: 29-34.
- Doddapattar P, Radović B, Patankar JV, Obrowsky S, Jandl K, et al. 2013. Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice. Mol Nutr Food Res 57(10): 1718-1728.
- Hill JO. Melanson EL, Wyatt, HT. 2000. Dietary fat intake and regulation of energy balance: implications for obesity. J Nutr 130: 284-288.
- Boden-albana B, Sacco RL. 2000. Lifestyle factors and stroke risk: exercise, alcohol, diet, obesity, smoking, drug use, and stress. Curr. Atheroscler Rep 2: 160-166.
- Tseng YH, Cypess AM, Kahn CR. 2010. Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov 9: 465–82.
- Park KW, Halperin DS, Tontonoz P. 2008. Before they were fat: adipocyte progenitors. Cell Metab 8: 454–7
- Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, et al. 2012. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150: 366–76.
- Lone J, Choi JH, Kim SW, Yun JW. 2016. Curcumin induces brown fat-like phenotype in 3T3-L1 and primary white adipocytes. J Nutr Biochem 27: 193–202.
- Legette LL, Luna AY, Reed RL, Miranda CL, Bobe G, et al. 2013. Xanthohumol lowers body weight and fasting plasma glucose in obese male Zucker fa/fa rats. Phytochemistry 91: 236–241.
- Yui, K., Kiyofuji, A, Osada, K. 2014. Effects of xanthohumol-rich extract from the hop on fatty acid metabolism in rats fed a high-fat diet. J Oleo Sci 63: 159–168.
- Miyata S, Inoue J, Shimizu M, Sato R. 2015. Xanthohumol improves diet-induced obesity and fatty liver by suppressing sterol regulatory element-binding protein (srebp) activation. J Biol Chem 290: 20565–20579.
- Miranda CL. Elias VD, Hay JJ, Choi J, Reed RL, et al. 2016. Xanthohumol improves dysfunctional glucose and lipid metabolism in diet-induced obese C57BL/6J mice. Arch Biochem Biophys 599: 22–30.
- Miranda CL, Johnson LA, de Montgolfier O, Elias VD, Ullrich LS, et al. 2018. Non-estrogenic Xanthohumol Derivatives Mitigate Insulin Resistance and Cognitive Impairment in High-Fat Diet-induced Obese Mice. Sci Rep 8(1): 613.
- Takahashi K, Osada K. 2017. Effect of Dietary Purified Xanthohumol from Hop (Humulus lupulus L.) Pomace on Adipose Tissue Mass, Fasting Blood Glucose Level, and Lipid Metabolism in KK-Ay Mice. J Oleo Sci 66(5): 531-541.
- Yang J-Y, Della-Fera MA, Rayalam S, Baile CA. 2007. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis: 12(11): 1953–63.
- Mendes V, Monteiro R, Pestana D, Teixeira D, Calhau C, et al. 2008. Xanthohumol Influences Preadipocyte Differentiation: Implication of Antiproliferative and Apoptotic Effects. J Agric Food Chem 56: (24):11631–7.
- Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820.
- Blake R, Trounce IA. 2014. Mitochondrial dysfunction and complications associated with diabetes. Biochim. Biophys. Acta 1840: 1404–1412.
- Costa R, Rodrigues I, Guardão L, Lima JQ, Sousa E. et al, 2017. Modulation of VEGF signaling in a mouse model of diabetes by xanthohumol and 8-prenylnaringenin: Unveiling the angiogenic paradox and metabolism interplay. Mol Nutr Food Res 61:(4).
- Costa R, Rodrigues I, Guardão L, Rocha-Rodrigues S, Silva C, et al. 2017. Xanthohumol and 8-prenylnaringenin ameliorate diabetic-related metabolic dysfunctions in mice. J Nutr Biochem. 45: 39-47.
- Kirkwood JS, Legette LL, Miranda CL, Jiang Y, Stevens JF. 2013. A metabolomics driven elucidation of the anti-obesity mechanisms of xanthohumol. J Biol Chem 288: 19000–19013.